RO123525B1 - Metodă in vitro de inducere selectivă a apoptozei sau de inhibare a proliferării celulelor ţintă care exprimă dr5 şi compoziţie pentru inducerea selectivă a apoptozei cuprinzând o combinaţie de anticorpi - Google Patents
Metodă in vitro de inducere selectivă a apoptozei sau de inhibare a proliferării celulelor ţintă care exprimă dr5 şi compoziţie pentru inducerea selectivă a apoptozei cuprinzând o combinaţie de anticorpi Download PDFInfo
- Publication number
- RO123525B1 RO123525B1 ROA200400390A RO200400390A RO123525B1 RO 123525 B1 RO123525 B1 RO 123525B1 RO A200400390 A ROA200400390 A RO A200400390A RO 200400390 A RO200400390 A RO 200400390A RO 123525 B1 RO123525 B1 RO 123525B1
- Authority
- RO
- Romania
- Prior art keywords
- antibody
- cells
- tra
- trail
- apoptosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34640201P | 2001-11-01 | 2001-11-01 | |
US39147802P | 2002-06-24 | 2002-06-24 | |
PCT/US2002/034420 WO2003038043A2 (en) | 2001-11-01 | 2002-10-25 | Combinations of dr5 antibody and other therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
RO123525B1 true RO123525B1 (ro) | 2013-04-30 |
Family
ID=26994839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ROA200400390A RO123525B1 (ro) | 2001-11-01 | 2002-10-25 | Metodă in vitro de inducere selectivă a apoptozei sau de inhibare a proliferării celulelor ţintă care exprimă dr5 şi compoziţie pentru inducerea selectivă a apoptozei cuprinzând o combinaţie de anticorpi |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1506285B1 (hu) |
JP (1) | JP4663232B2 (hu) |
KR (1) | KR20040081422A (hu) |
CN (1) | CN100506277C (hu) |
AT (1) | ATE491019T1 (hu) |
AU (1) | AU2002360307B2 (hu) |
BR (1) | BRPI0213846B8 (hu) |
CA (1) | CA2465314C (hu) |
CO (1) | CO5650175A2 (hu) |
DE (1) | DE60238560D1 (hu) |
HK (1) | HK1068914A1 (hu) |
HU (1) | HU230378B1 (hu) |
IL (2) | IL161686A0 (hu) |
MX (1) | MXPA04004184A (hu) |
NO (1) | NO333828B1 (hu) |
NZ (2) | NZ533164A (hu) |
PL (1) | PL216750B1 (hu) |
RO (1) | RO123525B1 (hu) |
RU (1) | RU2313368C2 (hu) |
WO (1) | WO2003038043A2 (hu) |
ZA (1) | ZA200403573B (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
EP1396500A4 (en) | 2001-05-18 | 2005-02-02 | Kirin Brewery | ANTI-TRAIL-R ANTIBODIES |
ES2328234T3 (es) | 2001-07-03 | 2009-11-11 | Genentech, Inc. | Anticuerpos dr4 humanos y utilizaciones de los mismos. |
EP2277887A3 (en) | 2001-10-19 | 2011-02-16 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
US7229617B2 (en) * | 2002-11-27 | 2007-06-12 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
AU2008201431B2 (en) * | 2002-11-27 | 2011-11-24 | Irm, Llc | Methods and compositions for inducing Apoptosis in cancer cells |
US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
JP2007508332A (ja) * | 2003-10-17 | 2007-04-05 | ノボ ノルディスク アクティーゼルスカブ | 併用療法 |
KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Dr5 항체 및 그의 용도 |
WO2006017859A2 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
JP5237638B2 (ja) | 2004-08-06 | 2013-07-17 | ジェネンテック, インコーポレイテッド | バイオマーカーを用いたアッセイおよび方法 |
EP1791864A2 (en) * | 2004-09-08 | 2007-06-06 | Genentech, Inc. | Methods of using death receptor ligands and cd20 antibodies |
CN101048428A (zh) * | 2004-09-08 | 2007-10-03 | 健泰科生物技术公司 | 利用死亡受体配体和cd20抗体的方法 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US8129124B2 (en) | 2005-02-02 | 2012-03-06 | The Uab Research Foundation | Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists |
AU2011259844B2 (en) * | 2005-02-02 | 2012-11-01 | The Uab Research Foundation | Agents and Methods Related to Reducing Resistance to Apoptosis- inducing Death Receptor Agonists |
JP2006265155A (ja) * | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
US8901281B2 (en) | 2005-06-17 | 2014-12-02 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
ES2380119T3 (es) | 2005-08-16 | 2012-05-08 | Genentech, Inc. | Sensibilidad apoptótica a APO2L/TRAIL analizando la expresión de GalNac-T14 en células/tejidos |
US7777008B2 (en) | 2006-06-19 | 2010-08-17 | Tolerx, Inc. | ILT3 binding molecules and uses therefor |
CA2665984C (en) | 2006-10-12 | 2017-02-28 | Activbiotics, Inc. | Superoxide dismutase mimetics for the treatment of oral mucositis |
CN101157729B (zh) * | 2007-10-23 | 2011-01-12 | 南京大学 | 一种肿瘤坏死因子相关凋亡配体变体及其应用 |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
ES2675847T3 (es) | 2010-10-29 | 2018-07-13 | Daiichi Sankyo Company, Limited | Nuevo anticuerpo anti-DR5 |
KR102030987B1 (ko) | 2011-04-25 | 2019-11-11 | 다이이찌 산쿄 가부시키가이샤 | 항 b7-h3항체 |
US9149483B2 (en) | 2011-09-26 | 2015-10-06 | Galera Labs, Llc | Methods for treatment of diseases |
HUE039000T2 (hu) | 2012-10-11 | 2018-12-28 | Daiichi Sankyo Co Ltd | Antitest-gyógyszer konjugát |
EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
CN104383520B (zh) * | 2013-08-19 | 2016-09-07 | 江苏靶标生物医药研究所有限公司 | 一种抗肿瘤药物组合物 |
CA2933666C (en) | 2013-12-25 | 2021-08-03 | Sapporo Medical University | Anti-trop2 antibody-drug conjugate |
DK3466976T3 (da) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
KR102624244B1 (ko) | 2014-04-10 | 2024-01-11 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
EP3250601A4 (en) | 2015-01-26 | 2018-07-11 | MacroGenics, Inc. | Multivalent molecules comprising dr5-binding domains |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
WO2017027728A1 (en) | 2015-08-11 | 2017-02-16 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
WO2017028279A1 (en) * | 2015-08-19 | 2017-02-23 | Beijing Cotimes Biotech Company Limited | Trail receptor-binding agents and uses of same |
IL258322B2 (en) | 2015-09-24 | 2023-10-01 | Daiichi Sankyo Co Ltd | Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof |
US11007251B2 (en) * | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
IL295620B2 (en) | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Cancer immunotherapy combined with a macrocyclic ring pentase complex |
CN108992671B (zh) * | 2017-06-06 | 2021-02-12 | 深圳市中科艾深医药有限公司 | 一种药物组合物及其制备治疗肝损伤的药物中的用途 |
MA49259A (fr) | 2017-06-07 | 2020-04-15 | Genmab Bv | Anticorps thérapeutiques à base d'hexamères d'igg mutées |
KR101951025B1 (ko) * | 2017-08-17 | 2019-02-21 | 서울대학교산학협력단 | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |
MA49987A (fr) | 2017-08-23 | 2020-07-01 | Daiichi Sankyo Co Ltd | Préparation de conjugué anticorps-médicament et lyophilisation associée |
CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
KR102630307B1 (ko) | 2017-08-31 | 2024-01-29 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
CN109810193B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
CN109810194B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
US20220008549A1 (en) | 2018-09-06 | 2022-01-13 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
CA3134403A1 (en) | 2019-03-25 | 2020-10-01 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
JPWO2020196474A1 (hu) | 2019-03-25 | 2020-10-01 | ||
SG11202112429PA (en) | 2019-05-29 | 2021-12-30 | Daiichi Sankyo Co Ltd | Dosage of an antibody-drug conjugate |
JPWO2021079958A1 (hu) | 2019-10-25 | 2021-04-29 | ||
IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
JPWO2021200131A1 (hu) | 2020-03-30 | 2021-10-07 | ||
AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
CA2301202A1 (en) * | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
ES2267547T3 (es) * | 1999-06-09 | 2007-03-16 | Genentech, Inc. | Sinergia de antagonista de receptores del ligando apo-2l y de cpt-11. |
US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
CA2384762A1 (en) * | 1999-09-15 | 2001-03-22 | Genentech, Inc. | Apo-2 receptor antibodies |
EP1272647B1 (en) * | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
-
2002
- 2002-10-25 HU HU0600602A patent/HU230378B1/hu unknown
- 2002-10-25 NZ NZ533164A patent/NZ533164A/en not_active IP Right Cessation
- 2002-10-25 JP JP2003540308A patent/JP4663232B2/ja not_active Expired - Fee Related
- 2002-10-25 AT AT02795556T patent/ATE491019T1/de not_active IP Right Cessation
- 2002-10-25 EP EP02795556A patent/EP1506285B1/en not_active Expired - Lifetime
- 2002-10-25 BR BRPI0213846A patent/BRPI0213846B8/pt not_active IP Right Cessation
- 2002-10-25 KR KR10-2004-7006688A patent/KR20040081422A/ko active Search and Examination
- 2002-10-25 MX MXPA04004184A patent/MXPA04004184A/es active IP Right Grant
- 2002-10-25 DE DE60238560T patent/DE60238560D1/de not_active Expired - Lifetime
- 2002-10-25 CA CA2465314A patent/CA2465314C/en not_active Expired - Lifetime
- 2002-10-25 AU AU2002360307A patent/AU2002360307B2/en not_active Ceased
- 2002-10-25 NZ NZ568727A patent/NZ568727A/en not_active IP Right Cessation
- 2002-10-25 IL IL16168602A patent/IL161686A0/xx unknown
- 2002-10-25 RU RU2004116476/13A patent/RU2313368C2/ru active
- 2002-10-25 WO PCT/US2002/034420 patent/WO2003038043A2/en active Search and Examination
- 2002-10-25 RO ROA200400390A patent/RO123525B1/ro unknown
- 2002-10-25 PL PL374061A patent/PL216750B1/pl unknown
- 2002-10-25 CN CNB028265327A patent/CN100506277C/zh not_active Expired - Lifetime
-
2004
- 2004-04-29 IL IL161686A patent/IL161686A/en active IP Right Grant
- 2004-05-11 ZA ZA2004/03573A patent/ZA200403573B/en unknown
- 2004-06-01 CO CO04051012A patent/CO5650175A2/es active IP Right Grant
- 2004-06-01 NO NO20042266A patent/NO333828B1/no not_active IP Right Cessation
-
2005
- 2005-02-17 HK HK05101330.2A patent/HK1068914A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2465314C (en) | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | |
US7981421B2 (en) | Combinations of antibodies selective for DR5 and other therapeutic agents | |
CA2465040C (en) | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof | |
US20030190687A1 (en) | Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof | |
AU2002360307A1 (en) | Combinations of DR5 antibody and other therapeutic agents | |
US20090208483A1 (en) | Antibody selective for dr4 and uses thereof | |
AU2002350121A1 (en) | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |